Critical Review: 111 (NASDAQ:YI) vs. Healthcare Triangle (NASDAQ:HCTI)

Healthcare Triangle (NASDAQ:HCTI) and 111 (NASDAQ:YI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a summary of current ratings and target prices for Healthcare Triangle and 111, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Healthcare Triangle	1	0	0	0	1.00
111	1	0	0	0	1.00

Volatility & Risk

Healthcare Triangle has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, 111 has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.

Valuation and Earnings

This table compares Healthcare Triangle and 111″s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Healthcare Triangle	$11.70 million	0.17	-$5.97 million	($6,047.91)	0.00
111	$1.97 billion	0.03	-$1.42 million	($0.84)	-7.43

111 has higher revenue and earnings than Healthcare Triangle. 111 is trading at a lower price-to-earnings ratio than Healthcare Triangle, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Healthcare Triangle and 111’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Healthcare Triangle	-48.85%	N/A	-59.99%
111	-0.52%	N/A	-2.70%

Insider & Institutional Ownership

0.3% of Healthcare Triangle shares are owned by institutional investors. Comparatively, 21.3% of 111 shares are owned by institutional investors. 0.1% of Healthcare Triangle shares are owned by company insiders. Comparatively, 43.9% of 111 shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

111 beats Healthcare Triangle on 7 of the 10 factors compared between the two stocks.

About Healthcare Triangle

Healthcare Triangle, Inc., a healthcare information technology company, focuses on developing solutions in the sectors of cloud services, data science, and professional and managed services for the electronic health record, and healthcare and life sciences industry. It provides a suite of software, solutions, platforms, and services that enables healthcare and pharma organizations to deliver personalized healthcare, precision medicine, advances in drug discovery, development and efficacy, collaborative research and development, respond to evidence, and accelerate their digital transformation. The company’s software platforms include CloudEz, an enterprise multi-cloud transformation and management platform that enables customers to manage their cloud infrastructure in private, hybrid, and public cloud infrastructures; and DataEz, a cloud-based data analytics and data science platform for the data analytics and data science requirements of life sciences/pharmaceutical and healthcare provider organizations. It also provides Readabl.AI, a Software-as-a-Service solution that uses public cloud artificial intelligence and machine learning to recognize and extract healthcare information from documents, faxes, and narrative reports. In addition, the company offers cloud IT services; and healthcare IT services, such as electronic health records and software implementation, optimization, and extension to community partners, as well as application managed services, and backup and disaster recovery on public cloud. It primarily serves healthcare delivery organizations, healthcare insurance companies, pharmaceutical and life sciences, biotech companies, and medical device manufacturers. The company was incorporated in 2019 and is based in Pleasanton, California. Healthcare Triangle, Inc. is a subsidiary of SecureKloud Technologies, Inc.

About 111

111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.